Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Common Equity: 2020-2024

Historic Common Equity for Maravai Lifesciences Holdings (MRVI) over the last 5 years, with Dec 2024 value amounting to $577.2 million.

  • Maravai Lifesciences Holdings' Common Equity fell 29.52% to $431.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $431.9 million, marking a year-over-year decrease of 29.52%. This contributed to the annual value of $577.2 million for FY2024, which is 26.92% down from last year.
  • Latest data reveals that Maravai Lifesciences Holdings reported Common Equity of $577.2 million as of FY2024, which was down 26.92% from $789.9 million recorded in FY2023.
  • In the past 5 years, Maravai Lifesciences Holdings' Common Equity ranged from a high of $905.2 million in FY2022 and a low of $154.7 million during FY2020.
  • In the last 3 years, Maravai Lifesciences Holdings' Common Equity had a median value of $789.9 million in 2023 and averaged $757.4 million.
  • In the last 5 years, Maravai Lifesciences Holdings' Common Equity spiked by 252.42% in 2021 and then fell by 26.92% in 2024.
  • Over the past 5 years, Maravai Lifesciences Holdings' Common Equity (Yearly) stood at $154.7 million in 2020, then soared by 252.42% to $545.4 million in 2021, then surged by 65.99% to $905.2 million in 2022, then decreased by 12.74% to $789.9 million in 2023, then decreased by 26.92% to $577.2 million in 2024.